Welcome to our dedicated page for MapLight Therapeutics news (Ticker: MPLT), a resource for investors and traders seeking the latest updates and insights on MapLight Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MapLight Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MapLight Therapeutics's position in the market.
MapLight Therapeutics (NASDAQ: MPLT) priced its initial public offering of 14,750,000 shares at $17.00 per share and granted underwriters a 30-day option to buy up to 2,212,500 additional shares.
The company also announced a concurrent private placement of 476,707 shares to affiliates of Goldman Sachs at the IPO price. Gross proceeds from the IPO and private placement are expected to be approximately $258.9 million before underwriting discounts, commissions, and expenses. Shares are expected to begin trading on the Nasdaq Global Market on October 27, 2025 under symbol MPLT, with the offering expected to close on October 28, 2025 subject to customary closing conditions.
